Today: 9 June 2026
Cerebras Jumps Again After Wall Street Calls Its AI Chip a Rival for Nvidia

Cerebras Jumps Again After Wall Street Calls Its AI Chip a Rival for Nvidia

NEW YORK, June 9, 2026, 06:02 EDT

Cerebras Systems was set to open higher on Tuesday, building on Monday’s rally. The move came after Wall Street banks started coverage on the fresh AI-chip IPO with upbeat calls. Shares traded at $246.53 premarket, up 3.66%. Cerebras closed Monday at $237.83, up 18.32%.

Cerebras is in focus as investors check demand for AI hardware names outside of Nvidia. The timing follows the end of the IPO quiet period, when banks involved in the offering were restricted from releasing research.

At least nine brokerages started coverage on Cerebras Monday, Reuters said, naming Morgan Stanley, Citigroup, Barclays and UBS among them. Morgan Stanley’s Joseph Moore and team pointed to strong demand for “fast, low-latency inference.” That’s when an AI model gives answers after it’s been trained. Reuters

Cerebras started trading on Nasdaq on May 14 with the ticker CBRS, wrapping its IPO the next day. The company moved 34.5 million Class A shares at $185 apiece after underwriters took up their whole option, for a total of around $6.38 billion before fees and expenses.

Cerebras isn’t positioning itself as just another GPU vendor. The GPU, or graphics processing unit, is the chip that has driven most of the AI surge. Cerebras takes a different tack, making a wafer-scale engine—bigger than standard processors—to reduce delays from networking lots of smaller chips.

Nvidia is the usual yardstick here. Cerebras claims its WSE-3 chip is 58 times bigger than a top GPU, and says it can do inference as much as 15 times faster than leading GPU-based systems. The company cautions the numbers depend on workload, setup and model.

OpenAI is part of the bullish argument. Cerebras disclosed in January a multi-year agreement with OpenAI to start deploying 750 megawatts of its wafer-scale hardware from 2026. Sachin Katti, who runs compute infrastructure at OpenAI, said Cerebras provides a “dedicated low-latency inference solution” for the platform. Cerebras

Amazon has a role here. In March, AWS and Cerebras said they would work together on a system that links AWS Trainium with Cerebras CS-3, using Amazon Bedrock. AWS’s David Brown called speed a “critical bottleneck” for tougher AI jobs. Cerebras

Cerebras has been a bumpy name since its debut. The stock priced at $185, started trading at $350, topped out at $386 that same day and finished at $311. It then slid down to $201 last Friday before bouncing back on Monday.

Concentration and execution remain key risks here. Barron’s said some of the caution on the stock is tied to Cerebras leaning heavily on one big OpenAI cloud deal, which makes up most of its $24.6 billion backlog for 2025, even with its AWS partnership bringing in other customers. If OpenAI orders change, delays hit deployments, or Nvidia and AMD push back harder, the scarcity premium driving CBRS could disappear fast.

Cerebras is being seen on Wall Street as one of the purer plays on rapid AI inference among listed names. That story is driving interest, but the shares remain jumpy.

Stock Market Today

  • Washington's Railroad Rule Changes Threaten U.S. Supply Chain
    June 9, 2026, 9:15 AM EDT. Congress and the White House are quietly imposing new regulations on U.S. railroads, a critical component of the national economy. These changes, seen as micromanagement, could disrupt freight movement and supply chains. The timing raises concerns amid ongoing economic pressures and recovery efforts post-pandemic. Rail networks handle bulk goods and industrial materials vital to commerce. Industry experts warn that increased federal oversight may hinder operational efficiency and investment. Delays or inefficiencies in rail transport could ripple through markets, affecting costs and delivery times across sectors. Stakeholders urge a balanced approach to regulation to ensure infrastructure resilience without stifling rail companies' flexibility and growth.

Latest articles

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

9 June 2026
Factorial Energy surged 16% to $13.80 in its Nasdaq debut as FAC, with premarket trading near $20.70, after replacing CGCT via SPAC merger that raised over $100 million for battery commercialization and implied a $1.3 billion equity value; former CGCT shares now trade as FAC, with founders retaining majority voting power and staged lock-up releases ahead.
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

9 June 2026
Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
Snap Shares Fall Even as Nasdaq Gains; June 16 in Focus

Snap Shares Fall Even as Nasdaq Gains; June 16 in Focus

9 June 2026
Snap Inc. shares fell 1.9% to $5.65, underperforming a rising Nasdaq and leaving the stock 46% below its 52-week high, as investors weigh weak ad revenue growth, North American user declines, and cost-cutting moves against ongoing competitive pressure from Meta and TikTok.
Nu Holdings Stock Moves in Early Trading as Buyback Lifts Shares, Credit-Cost Concerns Remain
Previous Story

Nu Holdings Stock Moves in Early Trading as Buyback Lifts Shares, Credit-Cost Concerns Remain

Micron Shares Edge Higher Again, But AI Memory Push Still Has a Snag
Next Story

Micron Shares Edge Higher Again, But AI Memory Push Still Has a Snag

Go toTop